On August 4, MEDBOT-B rose 5.17% in regular trading, trading at HK$22.4/share, with turnover of HK$70.14 million.

On the news front, Dahua Capital recently initiated coverage with a Buy rating and a HK$29 target price, citing the company's 5G remote surgery capabilities and global expansion, projecting a 73.8% revenue CAGR from 2025 to 2028. This follows the company's positive profit alert issued in late July, forecasting its first-ever half-year net profit of RMB 28-40 million, versus a net loss of RMB 115 million in the prior-year period.

Fundamentally, the turnaround was driven by revenue surging 200%-230% year-over-year, with the Toumai laparoscopic surgical robot achieving overseas revenue growth exceeding 450%. Global commercial installations have surpassed 200 units with orders exceeding 300 units across more than 60 countries. Gross margin improved by over 15 percentage points, while operating expense ratios continued to decline, reflecting enhanced operational efficiency.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)